Amundi Has $16.63 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Amundi raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 529.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 176,952 shares of the medical equipment provider's stock after buying an additional 148,842 shares during the quarter. Amundi owned 0.25% of Lantheus worth $16,633,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Lantheus during the 4th quarter valued at about $36,183,000. Groupama Asset Managment bought a new position in Lantheus during the third quarter worth about $439,000. Swedbank AB boosted its holdings in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Keybank National Association OH bought a new stake in shares of Lantheus in the 4th quarter valued at approximately $27,526,000. Finally, Janus Henderson Group PLC grew its stake in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock valued at $393,844,000 after purchasing an additional 257,022 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LNTH. The Goldman Sachs Group initiated coverage on Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price for the company. JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $132.86.

Remove Ads

Lantheus Price Performance

Shares of LNTH stock traded up $1.66 during trading hours on Monday, hitting $102.76. 492,160 shares of the company's stock were exchanged, compared to its average volume of 941,283. Lantheus Holdings, Inc. has a 52 week low of $56.44 and a 52 week high of $126.89. The stock has a market cap of $7.04 billion, a price-to-earnings ratio of 17.10 and a beta of 0.38. The stock's 50-day moving average is $92.07 and its 200-day moving average is $96.68.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.